Elevated plasma matrix metalloproteinases and their tissue inhibitors in patients with severe sepsis.

[1]  Alejandro Jiménez,et al.  Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis , 2009, Critical care.

[2]  K. Reinhart,et al.  Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated) , 2008, Critical care.

[3]  L. March,et al.  Differential regulation of matrix metalloproteinase 2 and matrix metalloproteinase 9 by activated protein C: relevance to inflammation in rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[4]  Ava K. Chow,et al.  Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature , 2007, British journal of pharmacology.

[5]  Hye-Youn Cho,et al.  Protective Role of Matrix Metalloproteinase-9 in Ozone-Induced Airway Inflammation , 2007, Environmental health perspectives.

[6]  C. Furuse,et al.  Hydrocortisone affects the expression of matrix metalloproteinases (MMP-1, -2, -3, -7, and -11) and tissue inhibitor of matrix metalloproteinases (TIMP-1) in human gingival fibroblasts. , 2007, Journal of periodontology.

[7]  Aubrey Hargrave,et al.  Antibody microarray analysis of inflammatory mediator release by human leukemia T cells and human non‐small cell lung cancer cells , 2007, Journal of biomolecular techniques : JBT.

[8]  X. Puente,et al.  LPS Responsiveness and Neutrophil Chemotaxis In Vivo Require PMN MMP-8 Activity , 2007, PloS one.

[9]  Andrew J. Ewald,et al.  Matrix metalloproteinases and the regulation of tissue remodelling , 2007, Nature Reviews Molecular Cell Biology.

[10]  R. Gemeinhart,et al.  Matrix metalloproteases: Underutilized targets for drug delivery , 2007, Journal of drug targeting.

[11]  José A Fernández,et al.  Activated protein C inhibits tissue plasminogen activator–induced brain hemorrhage , 2006, Nature Medicine.

[12]  M. Lalu,et al.  Matrix metalloproteinases contribute to endotoxin and interleukin‐1β induced vascular dysfunction , 2006, British journal of pharmacology.

[13]  C. Esmon,et al.  Inflammation and the activated protein C anticoagulant pathway. , 2006, Seminars in thrombosis and hemostasis.

[14]  M. Borggrefe,et al.  Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: Prognostic value of TIMP-1 in severe sepsis , 2006, Scandinavian journal of infectious diseases.

[15]  A. Noël,et al.  Resistance of Collagenase-2 (Matrix Metalloproteinase-8)-Deficient Mice to TNF-Induced Lethal Hepatitis1 , 2005, The Journal of Immunology.

[16]  G. Bernard,et al.  Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment* , 2005, Critical care medicine.

[17]  S. Foster,et al.  PEPTIDOGLYCAN OF STAPHYLOCCUS AUREUS INDUCES ENHANCED LEVELS OF MATRIX METALLOPROTEINASE-9 IN HUMAN BLOOD ORIGINATING FROM NEUTROPHILS , 2005 .

[18]  T. Turpeenniemi‐Hujanen,et al.  Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. , 2005, Biochimie.

[19]  M. Loeb,et al.  Patients with severe sepsis vary markedly in their ability to generate activated protein C. , 2004, Blood.

[20]  C. Jackson,et al.  Activated protein C stimulates proliferation, migration and wound closure, inhibits apoptosis and upregulates MMP-2 activity in cultured human keratinocytes. , 2004, Experimental cell research.

[21]  G. Murphy,et al.  Matrix metalloproteinases at a glance , 2004, Journal of Cell Science.

[22]  P. Liaw.  Endogenous protein C activation in patients with severe sepsis , 2004, Critical care medicine.

[23]  S. Maitra,et al.  Inhibition of Matrix Metalloproteinases by Chemically Modified Tetracyclines in Sepsis , 2003, Shock.

[24]  A. Sollevi,et al.  Differential release of matrix metalloproteinase‐9 and nitric oxide following infusion of endotoxin to human volunteers , 2003, Acta anaesthesiologica Scandinavica.

[25]  G. Opdenakker,et al.  Analysis of Gelatinases in Complex Biological Fluids and Tissue Extracts , 2002, Laboratory Investigation.

[26]  J. Wallace,et al.  Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. , 2002, Blood.

[27]  G. Opdenakker,et al.  Gelatinase B deficiency protects against endotoxin shock , 2002, European journal of immunology.

[28]  A. Aljada,et al.  Hydrocortisone Suppresses Intranuclear Activator-Protein-1 (AP-1) Binding Activity in Mononuclear Cells and Plasma Matrix Metalloproteinase 2 and 9 (MMP-2 and MMP-9) , 2001 .

[29]  J. Helterbrand,et al.  Low levels of protein C are associated with poor outcome in severe sepsis. , 2001, Chest.

[30]  N. Webster,et al.  Matrix metalloproteinase‐9 concentrations in critically ill patients , 2001, Anaesthesia.

[31]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[32]  J. Hwang,et al.  Functional role of matrix metalloproteinases (MMPs) in mammary epithelial cell development , 2001, Journal of cellular physiology.

[33]  Inge Nelissen,et al.  Gelatinase B functions as regulator and effector in leukocyte biology , 2001, Journal of leukocyte biology.

[34]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[35]  P. E. Van den Steen,et al.  Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. , 2000, Blood.

[36]  C. Overall,et al.  Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. , 2000, Science.

[37]  A. Stalder,et al.  Regulation of matrix metalloproteinases and their inhibitor genes in lipopolysaccharide-induced endotoxemia in mice. , 2000, The American journal of pathology.

[38]  Minh N. H. Nguyen,et al.  Activated Protein C Directly Activates Human Endothelial Gelatinase A* , 2000, The Journal of Biological Chemistry.

[39]  L. Matrisian,et al.  Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. , 1999, Science.

[40]  C. Liang,et al.  Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. , 1999, American journal of respiratory cell and molecular biology.

[41]  T. Nakamura,et al.  Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock: effect of fiber-immobilized polymyxin B treatment. , 1998, The American journal of the medical sciences.

[42]  C. Natanson,et al.  The sirens' songs of confirmatory sepsis trials: selection bias and sampling error. , 1998, Critical care medicine.

[43]  L. Matrisian,et al.  Matrilysin expression and function in airway epithelium. , 1998, The Journal of clinical investigation.

[44]  P. Libby,et al.  Generation of Biologically Active IL-1β by Matrix Metalloproteinases: A Novel Caspase-1-Independent Pathway of IL-1β Processing , 1998, The Journal of Immunology.

[45]  R. Bone,et al.  Sepsis: a new hypothesis for pathogenesis of the disease process. , 1997, Chest.

[46]  C. Sprung,et al.  Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. , 1995, Critical care medicine.

[47]  H. Sengeløv,et al.  Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. , 1993, The Journal of biological chemistry.

[48]  C. Esmon,et al.  Inflammation and Coagulation: Linked Processes Potentially Regulated Through a Common Pathway Mediated by Protein C , 1991, Thrombosis and Haemostasis.

[49]  E. Draper,et al.  APACHE II: A severity of disease classification system , 1985, Critical care medicine.

[50]  S. Weiss,et al.  Oxidative autoactivation of latent collagenase by human neutrophils. , 1985, Science.

[51]  R. Kizek,et al.  Matrix metalloproteinases. , 2010, Current medicinal chemistry.

[52]  H. Showell,et al.  Mechanism of Action , 2007 .

[53]  T. Pruett.  Matrix Metalloproteinase-9 Deficiency Impairs Host Defense against Abdominal Sepsis , 2007 .

[54]  S. Foster,et al.  Peptidoglycan of Staphylococcus aureus induces enhanced levels of matrix metalloproteinase-9 in human blood originating from neutrophils. , 2005, Shock.

[55]  A. Aljada,et al.  Hydrocortisone suppresses intranuclear activator-protein-1 (AP-1) binding activity in mononuclear cells and plasma matrix metalloproteinase 2 and 9 (MMP-2 and MMP-9). , 2001, The Journal of clinical endocrinology and metabolism.

[56]  P. Libby,et al.  Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. , 1998, Journal of immunology.

[57]  H. Birkedal‐Hansen.  Proteolytic remodeling of extracellular matrix. , 1995, Current opinion in cell biology.

[58]  A. H. Drummond,et al.  Processing of tumour necrosis factor-alpha precursor by metalloproteinases. , 1994, Nature.

[59]  Carlos López-Otín,et al.  The FASEB Journal • Research Communication Increased inflammation delays wound healing in mice deficient in collagenase-2 (MMP-8) , 2022 .